A clinical case of performing risk-reducing surgery with simultaneous implant reconstruction with a mutation in the BRCA1 gene

The article highlights the issue of the possibility of performing risk-reducing mastectomy as a cancer prevention for hereditary diseases. A review of the scientific literature has been conducted confirming the advantage of this operation. A clinical case of bilateral subcutaneous mastectomy with simultaneous implant reconstruction in the presence of a mutation in the BRCA1 gene is described.

1. State of oncological care in Russia in 2023. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 262 p. (In Russ.).

2. Global Cancer Observatory: Cancer Today. Available at: https://gco.iarc.fr/today/home

3. Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–30. DOI: 10.1086/375033

4. Kuchenbaecker K.B., Hopper J.L., Barnes D.R. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:2402–16. DOI: 10.1001/jama.2017.7112

5. Hartmann L.C., Schaid D.J., Woods J.E. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340(2):77–84. DOI: 10.1056/NEJM199901143400201

6. Rebbeck T.R., Friebel T., Lynch H.T. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004;22(6):1055–62. DOI: 10.1200/JCO.2004.04.188

7. Portnoy S.M., Zhordania K.I. The role of preventive surgery in patients with BRCA-associated breast cancer and ovarian cancer. Meditsinskiye tekhnologii. Otsenka i vybor = Medical Technologies. Evaluation and Selection 2012;2(8):114–8. (In Russ.).

8. Breast Cancer. Clinical Practice Guidelines, 2021. Available at: https://cr.minzdrav.gov.ru/view-cr/379_4. (In Russ.).

9. Benign breast dysplasia. Clinical guidelines, 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/598_3 (In Russ.).

10. Gradishar W.J., Anderson B.O., Abraham J. et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 2020;18(4):452–78. DOI: 10.6004/jnccn.2020.0016

11. Goldhirsch A., Winer E.P., Coates A.S. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24(9):2206–23. DOI: 10.1093/annonc/mdt303

12. Cardoso F., Paluch-Shimon S., Senkus E. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31(12):1623–49. DOI: 10.1016/j.annonc.2020.09.010